NO20054336L - Blandinger og fremgangsmate for diagnostisering og behandling av astma eller andre allergiske eller inflammatoriske sykdommer - Google Patents

Blandinger og fremgangsmate for diagnostisering og behandling av astma eller andre allergiske eller inflammatoriske sykdommer

Info

Publication number
NO20054336L
NO20054336L NO20054336A NO20054336A NO20054336L NO 20054336 L NO20054336 L NO 20054336L NO 20054336 A NO20054336 A NO 20054336A NO 20054336 A NO20054336 A NO 20054336A NO 20054336 L NO20054336 L NO 20054336L
Authority
NO
Norway
Prior art keywords
component
asthma
allergic
inflammatory diseases
methods
Prior art date
Application number
NO20054336A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054336D0 (no
Inventor
Michael R Bowman
Debra Ellis
Maximillian T Follettie
Aaron Winkler
Cara Williams
Heng Chen
Wei Liu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20054336D0 publication Critical patent/NO20054336D0/no
Publication of NO20054336L publication Critical patent/NO20054336L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03001—Arginase (3.5.3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
NO20054336A 2003-03-04 2005-09-20 Blandinger og fremgangsmate for diagnostisering og behandling av astma eller andre allergiske eller inflammatoriske sykdommer NO20054336L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45139603P 2003-03-04 2003-03-04
US47587003P 2003-06-05 2003-06-05
PCT/US2004/006470 WO2005003164A2 (fr) 2003-03-04 2004-03-04 Compositions et procedes pour le diagnostic et le traitement de l'asthme et d'autres maladies allergiques ou inflammatoires

Publications (2)

Publication Number Publication Date
NO20054336D0 NO20054336D0 (no) 2005-09-20
NO20054336L true NO20054336L (no) 2005-12-02

Family

ID=33567303

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054336A NO20054336L (no) 2003-03-04 2005-09-20 Blandinger og fremgangsmate for diagnostisering og behandling av astma eller andre allergiske eller inflammatoriske sykdommer

Country Status (11)

Country Link
US (2) US20040234517A1 (fr)
EP (1) EP1599587A2 (fr)
JP (1) JP2007537984A (fr)
KR (1) KR20050106483A (fr)
AU (1) AU2004253846A1 (fr)
BR (1) BRPI0408004A (fr)
CA (1) CA2517684A1 (fr)
MX (1) MXPA05009251A (fr)
NO (1) NO20054336L (fr)
RU (2) RU2005130636A (fr)
WO (1) WO2005003164A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090298912A1 (en) * 2005-07-01 2009-12-03 The Johns Hopkins University Arginase II: A Target treatment of aging heart and heart failure
WO2007032717A1 (fr) * 2005-08-03 2007-03-22 Astrazeneca Ab Procédé d’identification d’un agent qui module le transport d’arginine dans un chondrocyte
JP2009511586A (ja) * 2005-10-11 2009-03-19 ワシントン・ユニバーシティ 気道分泌過多を治療するための組成物および方法
US20100056480A1 (en) * 2006-11-21 2010-03-04 Rijks Univesiteit Groningen Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
WO2008091814A2 (fr) * 2007-01-22 2008-07-31 Wyeth Évaluation de l'asthme et d'une expression d'un gène dépendant d'un allergène
ATE504296T1 (de) * 2007-03-06 2011-04-15 Rachid Ennamany Zusammensetzung auf basis von rutin und l-lysin
US8541183B2 (en) 2007-09-11 2013-09-24 Cancer Prevention And Cure, Ltd. Methods of identification, assessment, prevention and therapy of lung diseases and kits thereof
ES2703714T3 (es) * 2009-03-12 2019-03-12 Cancer Prevention & Cure Ltd Métodos de identificación, evaluación, prevención y terapia de enfermedades pulmonares y kits de los mismos, incluida la identificación, evaluación, prevención y terapia de enfermedades en base al género
GB201007556D0 (en) * 2010-05-06 2010-06-23 Wetenschappelijk En Tech Ct Va Methods and compositions for textile layers and coatings
US8895528B2 (en) * 2010-05-26 2014-11-25 Curna, Inc. Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
KR102008708B1 (ko) * 2010-06-23 2019-08-08 큐알엔에이, 인크. 전압 작동 나트륨 통로, 알파 소단위(scna)에 대한 자연 안티센스 전사체의 저해에 의한 전압 작동 나트륨 통로, 알파 소단위(scna) 관련된 질환의 치료
EP3137103B1 (fr) * 2014-04-29 2021-10-20 Bio-Cancer Treatment International Ltd. Méthodes et compositions pour la modulation du système immunitaire à l'aide de l'arginase i
CN110709936A (zh) 2017-04-04 2020-01-17 肺癌蛋白质组学有限责任公司 用于早期肺癌预后的基于血浆的蛋白质概况分析
CA3190519A1 (fr) * 2020-08-26 2022-03-03 Cila Therapeutics Inc. Agents therapeutiques inhalables

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4489710A (en) * 1981-06-23 1984-12-25 Xoma Corporation Composition and method for transplantation therapy
DE3280400D1 (de) * 1981-10-23 1992-06-04 Molecular Biosystems Inc Oligonukleotides heilmittel und dessen herstellungsverfahren.
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4625014A (en) * 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4638045A (en) * 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5266464A (en) * 1988-02-10 1993-11-30 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
US4980281A (en) * 1988-02-10 1990-12-25 Housey Gerard M Method of screening for protein inhibitors and activators
US5688655A (en) * 1988-02-10 1997-11-18 Ict Pharmaceuticals, Inc. Method of screening for protein inhibitors and activators
US5459039A (en) * 1989-05-12 1995-10-17 Duke University Methods for mapping genetic mutations
US5866123A (en) * 1990-04-13 1999-02-02 Research Development Foundation Gene encoding cationic amino acid transporter protein
US6784163B1 (en) * 1990-04-13 2004-08-31 Macleod Carol L. Inhibition of cationic amino acid transporter protein and uses thereof
GB9509757D0 (en) * 1995-05-13 1995-07-05 Ilford Ltd Toning of photographic print material
WO2002015895A2 (fr) * 2000-08-24 2002-02-28 The Regents Of The University Of California Alpha-difluoromethylornithine (dfmo) utile pour supprimer les taux de polyamine prostatique chez l'homme
WO2003073990A2 (fr) * 2002-03-01 2003-09-12 Children's Hospital Medical Center Traitement de l'asthme ou des allergies
AU2003218099A1 (en) * 2002-03-12 2003-09-29 Lsu Medical Center Modulation of the immune response through the manipulation of arginine levels
CA2515929C (fr) * 2003-02-14 2013-11-19 Children's Hospital & Research Center At Oakland Traitement d'etats pathologiques associes a la biodisponibilite reduite de l'oxyde nitrique, y compris des etats pathologiques causes par l'activite elevee de l'arginase

Also Published As

Publication number Publication date
US20040234517A1 (en) 2004-11-25
KR20050106483A (ko) 2005-11-09
JP2007537984A (ja) 2007-12-27
EP1599587A2 (fr) 2005-11-30
AU2004253846A1 (en) 2005-01-13
US20090156537A1 (en) 2009-06-18
RU2008145510A (ru) 2010-05-27
WO2005003164A9 (fr) 2006-07-20
WO2005003164A2 (fr) 2005-01-13
WO2005003164A3 (fr) 2005-05-12
MXPA05009251A (es) 2005-10-19
NO20054336D0 (no) 2005-09-20
CA2517684A1 (fr) 2005-01-13
BRPI0408004A (pt) 2006-02-14
RU2005130636A (ru) 2006-05-10

Similar Documents

Publication Publication Date Title
NO20054336L (no) Blandinger og fremgangsmate for diagnostisering og behandling av astma eller andre allergiske eller inflammatoriske sykdommer
Yuan et al. Metallodrug ranitidine bismuth citrate suppresses SARS-CoV-2 replication and relieves virus-associated pneumonia in Syrian hamsters
Chang et al. Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects
EA201001821A1 (ru) Производные триазола, полезные для лечения заболеваний
Guimarães et al. Implications of SARS-Cov-2 infection on eNOS and iNOS activity: Consequences for the respiratory and vascular systems
EA200870380A1 (ru) Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-vi для лечения или предупреждения диабета
WO2007070434A3 (fr) Amino-piperidines fusionnees en tant qu'inhibiteurs de la dipeptidyl peptidase-4 pour le traitement ou la prevention du diabete
DE602007009839D1 (de) Imidazo ä1,2-aüpyridin-2-carboxamid-derivate, herstellungsverfahren und ihre verwendung für therapeutika
NO20091620L (no) Boronsyre og estere som inhibitorer av fettsyreamidhydrolaser
WO2007087231A3 (fr) Aminocyclohexanes utiles en tant qu'inhibiteurs de la dipeptidyl peptidase-iv pour traiter ou prévenir le diabète
NO20084005L (no) Aminderivater
EA201201650A1 (ru) Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
MY150787A (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of prevention of diabetes
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
WO2007097931A3 (fr) Aminotétrahydropyrannes en tant qu'inhibiteurs de dipeptidylpeptidase-iv dans le traitement prophylactique ou thérapeutique du diabète
WO2007136603A3 (fr) Aminotétrahydropyranes en tant qu'inhibiteurs de la dipeptidyl peptidase-iv pour le traitement ou la prévention du diabète
WO2011056985A3 (fr) Composés hétérocycliques substitués
UY32062A (es) Inhibidores de beta-secretasa
EA201171333A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-с-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
MX2009004475A (es) Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
EP1819674A4 (fr) Aminopiperidines fusionnees utilisees comme inhibiteurs de la dipeptidyle peptidase-iv permettant de traiter ou de prevenir le diabete
BR112015012366A8 (pt) antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido
NO20080150L (no) Inhibitorer av AKT-aktivitet
IL195030A (en) IV dpp inhibitor assemblies
NO20054957L (no) Subtituerte karboksylsyrer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application